We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
- Authors
Oshima, K.; Takahashi, T.; Mori, T.; Matsuyama, T.; Usuki, K.; Asano-Mori, Y.; Nakahara, F.; Okamoto, S.; Kurokawa, M.; Kanda, Y.
- Abstract
K. Oshima, T. Takahashi, T. Mori, T. Matsuyama, K. Usuki, Y. Asano-Mori, F. Nakahara, S. Okamoto, M. Kurokawa, Y. Kanda. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group Transpl Infect Dis 2010: 12: 421-427. All rights reserved Varicella zoster virus (VZV) disease is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). We carried out a trial of 1-year low-dose valacyclovir (VCV) prophylaxis against VZV disease to evaluate its efficacy and safety. Patients received oral acyclovir (ACV) 1000 mg/day until day 35 after HSCT. Oral VCV 500 mg/day, 3 times a week, was started on day 36 and continued until 1 year after HSCT. The development of VZV disease was monitored until 2 years after HSCT. A total of 40 patients with a median age of 43 years were enrolled. VCV was well tolerated in all but 1 patient who discontinued it on day 224 because of thrombocytopenia of unknown cause. Seven patients developed VZV disease at a median of 479 days (range 145-651) after HSCT, with a cumulative incidence of 18.5%. Two patients developed breakthrough disease during VCV prophylaxis. The other 5 patients developed VZV disease after the discontinuation of VCV, and 3 of these had developed extensive chronic graft-versus-host disease. Visceral involvement and serious complications were completely eliminated. All patients responded to the therapeutic dose of VCV or ACV. One-year low-dose VCV can be safely and effectively administered for the prevention of VZV disease after allogeneic HSCT.
- Subjects
VARICELLA-zoster virus; HEMATOPOIETIC stem cell transplantation; ACYCLOVIR; THROMBOCYTOPENIA; DISEASE complications; GRAFT versus host disease; LONGITUDINAL method
- Publication
Transplant Infectious Disease, 2010, Vol 12, Issue 5, p421
- ISSN
1398-2273
- Publication type
Article
- DOI
10.1111/j.1399-3062.2010.00541.x